IZUMO family member 2Genealiases: C19orf41 · PLAL6978 · PRO21961 · SCRL
Q-omics provides the consensus-scored IZUMO2 profile across patient tissues and cancer cell-line models. IZUMO2 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, IZUMO2 is differentially expressed in 9, with the highest sampling consensus in COAD. Additionally, IZUMO2 RNA expression shows 7,255 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, COAD, and TGCT as cancer lineages where IZUMO2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IZUMO2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IZUMO2 survival associations across molecular data types. IZUMO2 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (6) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IZUMO2 RNA expression–survival associations across cancer types. High IZUMO2 expression shows unfavorable associations in KIRC and KIRP, but favorable associations in SKCM, READ, UVM and THCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for IZUMO2 RNA expression.
This table summarizes IZUMO2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for IZUMO2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IZUMO2 shows lower tumor expression in KIRC, THCA, KICH and PRAD and higher tumor expression in COAD and HNSC. The COAD box plot shows higher IZUMO2 RNA expression in tumor versus normal tissue (log2 FC = +0.706, t-test p < 0.001).
This table shows molecular features associated with IZUMO2 in patient tissues and cancer cell lines. In patient samples, IZUMO2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, IZUMO2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and SOFT_TISSUE.
